Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ACAD

ACAD - ACADIA Pharmaceuticals Inc Stock Price, Fair Value and News

$25.62-0.58 (-2.21%)
Market Closed

72/100

ACAD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

72/100

ACAD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$33.39

Target 3M

$28.34

Target 6M

$29.93

ACAD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACAD Price Action

Last 7 days

-4.3%

Last 30 days

-6.0%

Last 90 days

12.7%

Trailing 12 Months

39.2%

ACAD RSI Chart

ACAD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACAD Valuation

Market Cap

4.3B

Price/Earnings (Trailing)

16.6

Price/Sales (Trailing)

4.14

EV/EBITDA

14.85

Price/Free Cashflow

18.48

ACAD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$33.39

Target 3M

$28.34

Target 6M

$29.93

ACAD Fundamentals

ACAD Revenue

Revenue (TTM)

1.0B

Rev. Growth (Yr)

11.27%

Rev. Growth (Qtr)

5.32%

ACAD Earnings

Earnings (TTM)

261.2M

Earnings Growth (Yr)

119.07%

Earnings Growth (Qtr)

169.18%

ACAD Profitability

EBT Margin

26.14%

Return on Equity

28.47%

Return on Assets

19.63%

Free Cashflow Yield

5.41%

ACAD Investor Care

Shares Dilution (1Y)

1.68%

Diluted EPS (TTM)

1.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025996.3M1.0B1.0B0
2024813.8M890.5M929.2M957.8M
2023520.2M550.9M631.9M726.4M
2022493.1M512.4M511.5M517.2M
2021458.2M463.4M474.4M484.1M
2020366.2M393.1M419.1M441.8M
2019237.9M264.0M300.3M339.1M
2018158.5M185.1M207.8M223.8M
201740.2M63.0M93.3M124.9M
20164.4M8.7M13.0M17.3M
201500129.0K118.0K
2014758.0K335.0K110.0K120.0K
20134.9M4.7M1.5M1.1M
20122.1M2.2M5.1M4.9M
201132.1M22.1M12.1M2.1M
2010018.3M30.2M42.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About ACADIA Pharmaceuticals Inc

ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://acadia.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES540

ACADIA Pharmaceuticals Inc Frequently Asked Questions

ACAD is the stock ticker symbol of ACADIA Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ACADIA Pharmaceuticals Inc is 4.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ACAD's fair value in chart for subscribers.

The fair value guage provides a quick view whether ACAD is over valued or under valued. Whether ACADIA Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ACADIA Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACAD.

As of Wed Jan 28 2026, ACAD's PE ratio (Price to Earnings) is 16.6 and Price to Sales (PS) ratio is 4.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACAD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ACADIA Pharmaceuticals Inc has provided 0.022 (multiply by 100 for percentage) rate of return.